• Enveric Biosciences reported preclinical mouse study results showing EB-003 altered cortical brain activity with a profile distinct from psychedelic comparator DMT.
• EB-003 did not trigger the epileptic-like brain activity or acute body spasms observed with DMT.
• The findings support evaluating brain-wave monitoring in the planned Phase 1 trial to assess drug effects and guide dose selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104996165) on November 04, 2026, and is solely responsible for the information contained therein.